Preclinical safety validation of a stabilized viral vector direct injection approach to the cervical spinal cord.
The current lack of a validated intraspinal delivery approach precludes translation of promising cell or viral-based therapeutics for treatment of varied spinal cord afflictions. We have developed a stabilized cervical microinjection platform with the intent of precise delivery to intraspinal sites of interest. Nine 30-40 kg female swine underwent coordinate-based microinjection AAV2-GFP at three injected volumes (10, 25, and 50 microL (n= 3/group)) and matched infusion rates (1.0, 2.5, and 5.0 microL/min) over a period (t= 10 minutes). Preliminary validation is provided by behavioral and targeting data demonstrating safe delivery of a viral vector carrying a fluorescent reporter gene to the cervical spinal cord ventral horn.
Federici
Thais
T
Emory University School of Medicine, 1365B Clifton Rd. NE, Suite B6200, Atlanta, GA 30322, USA.
Riley
Jonathan
J
Park
John
J
Bain
Mark
M
Boulis
Nicholas
N
D000818:Animals; D000870:Anterior Horn Cells / Q000166:cytology; D001522:Behavior, Animal; D002574:Cervical Vertebrae / Q000378:metabolism*; D000229:Dependovirus / Q000235:genetics*; D005260:Female; D018014:Gene Transfer Techniques / Q000009:adverse effects*; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000009:adverse effects*; D049452:Green Fluorescent Proteins / Q000378:metabolism; D007278:Injections, Spinal; D008845:Microinjections; D034421:Sus scrofa
D049452:Green Fluorescent Proteins